HomeNew STAT Inhibitors

New STAT Inhibitors

Catalog No. Product Name Information
E6482 STAT3-IN-12 STAT3-IN-12 is a potent inhibitor of STAT3signaling, by effectively blocking IL-6-induced activation of the JAK/STAT3 pathway. STAT3-IN-12 suppresses cancer cell proliferation and migration, while promoting apoptosis and inducing cell cycle arrest.
E6446 SD-2301 SD-2301 is a potent and selective PROTAC-based STAT3 degrader that targets the VHL–cullin 2 complex, enhancing dendritic cell function and anti-tumor immunity. It synergizes with anti-PD-L1 therapy to robustly suppress tumor growth in vivo.
E5802 SD-436 SD-436 is a potent and selective PROTAC degrader of STAT3 with a DC50 of 0.5 μM. It induces complete and long-lasting tumor regression in leukemia and lymphoma xenograft models in mice.
E1990 KT-333 KT-333 is a first-in-class, potent, and selective heterobifunctional degrader of STAT3 that recruits the VHL E3 ligase for ubiquitin-proteasome-mediated degradation. It induces robust antitumor activity in preclinical models of ALK⁺ anaplastic large cell lymphoma (ALCL).
E6051 niclosamide ethanolamine Niclosamide ethanolamine (Niclosamide-olamine, BAY2353 olamine) is a mild mitochondrial uncoupler, anthelmintic agent, and highly potent inhibitor of STAT3 signaling pathway with an IC50 of 0.25 μM. It improves insulin levels, body weight, and muscle wasting, inhibits artery constriction, suppresses PI3K-mTORC1 signaling to block fibroblast proliferation, inhibits TGF-β1-induced EMT and ECM accumulation via the mTORC1-4EBP1 axis, activates noncanonical autophagy to sensitize fibroblasts to apoptosis, and confers renoprotection in diabetic and adriamycin-induced nondiabetic kidney disease models.
≡ All STAT Inhibitors